{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:25:39Z","timestamp":1793147139702,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012320","name":"Otto-von-Guericke-Universit\u00e4t Magdeburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Primary liver cancer is one of the most frequently diagnosed and deadliest cancers. Zinc finger E-box binding homeobox 1 (ZEB1) is negative prognostic factor in liver cancer by promoting therapy resistance and tumorigenesis. Interfering in pathways of cellular metabolism emerges as a potent strategy to overcome tumor cells resistance to therapy. Our study aims to investigate the apoptotic potential of pharmacological inhibition of mitochondrial metabolism in primary liver cancer and whether this strategy can reduce ZEB1-associated resistance to standard of care chemotherapy Sorafenib. ZEB1 mRNA levels in patient samples and cancer cell lines were computationally screened using public datasets. Transcript and protein abundance of ZEB1 and regulators of mitochondrial fission and fusion were quantified in patient-matched tumor and non-tumor tissues of hepatocellular carcinoma (HCC) and cholangiocellular adenocarcinoma (CCA) from our clinic and common liver cancer cell lines. Functional assays on cell models with varying ZEB1 expression exposed to mitochondrial division inhibitor Mdivi-1 included mitochondrial mass quantification, mitochondrial membrane potential examination, apoptosis, extracellular flux, and cell growth analyses. Mdivi-1 treatment in human-physiological achievable concentration effectively induced apoptosis in all tested cell models. ZEB1 expression was heightened in younger patients, and dynamin-related protein 1 (Drp1) protein abundance was elevated in a subgroup of tumor tissue compared to healthy tissue. Cancer cell lines with high ZEB1 expression showed increased mitochondrial fission marker Drp1 and larger total mitochondrial mass, preserved membrane potential with reduced mitochondrial ATP production and respiration, resulting in an overall reduced mitochondrial fitness. Pharmacological inhibition of mitochondrial fission using Mdivi-1 reduced HCC resistance to Sorafenib in ZEB1-driven liver cancer. A subset of HCC cell lines with elevated ZEB1 levels exhibit increased mitochondrial mass and reduced metabolic activity. Targeting mitochondrial division in HCC by treatment with Mdivi-1 in combination with Sorafenib demonstrates a synergistic therapeutic effect in hepatocellular carcinoma (HCC) cell lines characterized by high ZEB1 expression. Further in vivo validation is needed to confirm these findings and evaluate this potential combined treatment option.<\/jats:p>","DOI":"10.1038\/s41598-025-16379-6","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:16:40Z","timestamp":1755627400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"H.","family":"Freudenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Strecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gylstorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boettcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Medunjanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Siba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Y.","family":"Sanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Arend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Croner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6021-1841","authenticated-orcid":false,"given":"U. D.","family":"Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Stelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"2","key":"16379_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3350\/cmh.2023.0070","volume":"29","author":"JH Oh","year":"2023","unstructured":"Oh, J. H. & Jun, D. W. The latest global burden of liver cancer: A past and present threat. Clin. Mol. Hepatol. 29 (2), 355\u2013357. https:\/\/doi.org\/10.3350\/cmh.2023.0070 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"10125","key":"16379_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani, C., et al. Global surveillance of trends in cancer survival: analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers during 2000\u20132014 from 322 population-based registries in 71 countries (CONCORD-3). Lancet Lond. Engl. 391 (10125), 1023\u20131075. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3 (2018).","journal-title":"Lancet Lond. Engl."},{"issue":"1","key":"16379_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan, S. A., Tavolari, S. & Brandi, G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 39 (1), 19\u201331. https:\/\/doi.org\/10.1111\/liv.14095 (2019).","journal-title":"Liver Int."},{"key":"16379_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s40471-019-00188-3","volume":"6","author":"JL Petrick","year":"2019","unstructured":"Petrick, J. L. McGlynn, The changing epidemiology of primary liver cancer, curr. Epidemiol. Rep. 6, 2, 104\u2013111. https:\/\/doi.org\/10.1007\/s40471-019-00188-3 (2019).","journal-title":"Epidemiol. Rep."},{"key":"16379_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/apm.12917","volume":"127","author":"R El-Sheikh","year":"2019","unstructured":"El-Sheikh, R. et al. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. APMIS 127, 93\u2013105. https:\/\/doi.org\/10.1111\/apm.12917 (2019).","journal-title":"APMIS"},{"key":"16379_CR6","unstructured":"Cholangiocarcinoma: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology. Zugegriffen  https:\/\/www.nature.com\/articles\/s41575-020-0310-z (2020)."},{"issue":"1","key":"16379_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/0008-5472.CAN-17-2476","volume":"78","author":"J Caramel","year":"2018","unstructured":"Caramel, J., Ligier, M. & Puisieux, A. \u201ePleiotropic roles for ZEB1 in cancer. Cancer Res. 78 (1), 30\u201335. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2476 (2018).","journal-title":"Cancer Res."},{"key":"16379_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00036","author":"S Dr\u00e1pela","year":"2020","unstructured":"Dr\u00e1pela, S., Bouchal, J., Jolly, M. K. & Culig, Z. Sou\u010dek. ZEB1: A critical regulator of cell plasticity, DNA damage response, and therapy resistance. Front. Mol. Biosci. https:\/\/doi.org\/10.3389\/fmolb.2020.00036 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"16379_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41419-019-1885-6","volume":"10","author":"R Sreekumar","year":"2019","unstructured":"Sreekumar, R. Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. Cell. Death Dis. 10, 10, 703. https:\/\/doi.org\/10.1038\/s41419-019-1885-6 (2019).","journal-title":"Cell. Death Dis."},{"key":"16379_CR10","unstructured":"ZEB1 Fuels Serine Metabolism to Promote HCC Metastasis - PubMed. Zugegriffen: 16  https:\/\/pubmed.ncbi.nlm.nih.gov\/37517803\/ (2024)."},{"key":"16379_CR11","doi-asserted-by":"publisher","unstructured":"L.-Y. Li.  ZEB1 serves an oncogenic role in the tumourigenesis of HCC by promoting cell proliferation, migration, and inhibiting apoptosis via Wnt\/\u03b2-catenin signaling pathway. Acta Pharmacol. Sin. 42, 10, 1676\u20131689  https:\/\/doi.org\/10.1038\/s41401-020-00575-3 (2021).","DOI":"10.1038\/s41401-020-00575-3"},{"issue":"4","key":"16379_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jcmgh.2023.06.006","volume":"16","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. ZEB1 transcriptionally activates PHGDH to facilitate carcinogenesis and progression of HCC. Cell. Mol. Gastroenterol. Hepatol. 16 (4), 541\u2013556. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.06.006 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"2","key":"16379_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jhep.2014.03.033","volume":"61","author":"A Clap\u00e9ron","year":"2014","unstructured":"Clap\u00e9ron, A. et al. EGF\/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J. Hepatol. 61 (2), 325\u2013332. https:\/\/doi.org\/10.1016\/j.jhep.2014.03.033 (2014).","journal-title":"J. Hepatol."},{"key":"16379_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.diff.2019.04.001","volume":"107","author":"CW Chang","year":"2019","unstructured":"Chang, C. W., Lo, J. F., Wei, X. & Wang Roles of mitochondria in liver cancer stem cells, differ. Res. Biol. Divers. 107, 35\u201341. https:\/\/doi.org\/10.1016\/j.diff.2019.04.001 (2019).","journal-title":"Res. Biol. Divers."},{"key":"16379_CR15","doi-asserted-by":"publisher","unstructured":"Li, S. et al. \u201eFUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion. Nat. Commun. 13 (1), 3486  https:\/\/doi.org\/10.1038\/s41467-022-31187-6 (2022).","DOI":"10.1038\/s41467-022-31187-6"},{"key":"16379_CR16","doi-asserted-by":"publisher","unstructured":"Q. Huang. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways, autophagy. 12 (6), 999\u20131014  https:\/\/doi.org\/10.1080\/15548627.2016.1166318 (2016).","DOI":"10.1080\/15548627.2016.1166318"},{"key":"16379_CR17","unstructured":"ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM - PMC. Zugegriffen: 29  https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8058737\/ (2022)."},{"key":"16379_CR18","doi-asserted-by":"publisher","unstructured":"Jiang, H. Zeb1-induced metabolic reprogramming of Glycolysis is essential for macrophage polarization in breast cancer. Cell. Death Dis.  13 (3), 206 https:\/\/doi.org\/10.1038\/s41419-022-04632-z (2022).","DOI":"10.1038\/s41419-022-04632-z"},{"issue":"8","key":"16379_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41419-022-05194-w","volume":"13","author":"K Zhang","year":"2022","unstructured":"Zhang, K. et al. Zeb1 sustains hematopoietic stem cell functions by suppressing mitofusin-2-mediated mitochondrial fusion. Cell. Death Dis. 13 (8), 735. https:\/\/doi.org\/10.1038\/s41419-022-05194-w (2022).","journal-title":"Cell. Death Dis."},{"key":"16379_CR20","doi-asserted-by":"publisher","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y. & Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D1, D587\u2013D592  https:\/\/doi.org\/10.1093\/nar\/gkac963 (2023).","DOI":"10.1093\/nar\/gkac963"},{"issue":"11","key":"16379_CR21","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. Publ.  Protein Soc. 28 (11), 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci. Publ Protein Soc."},{"key":"16379_CR22","doi-asserted-by":"publisher","unstructured":"Vargas-Toscano, A. Rapalink-1 targets glioblastoma stem cells and acts synergistically with tumor treating fields to reduce resistance against Temozolomide. Cancers 12 3859  https:\/\/doi.org\/10.3390\/cancers12123859 (2020).","DOI":"10.3390\/cancers12123859"},{"key":"16379_CR23","doi-asserted-by":"publisher","unstructured":"Chen, W. Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF\/c-Met\/Akt and Jak2\/Stat3 Pathways. BioMed Res. Int. 764981   https:\/\/doi.org\/10.1155\/2014\/764981 (2014).","DOI":"10.1155\/2014\/764981"},{"key":"16379_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 2, 440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947 (2010).","journal-title":"Cancer Res."},{"issue":"8010","key":"16379_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41586-024-07282-7","volume":"629","author":"JP Auger","year":"2024","unstructured":"Auger, J. P. et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature 629 (8010), 184\u2013192. https:\/\/doi.org\/10.1038\/s41586-024-07282-7 (2024).","journal-title":"Nature"},{"key":"16379_CR26","doi-asserted-by":"publisher","unstructured":"Paul, B., Lewinska, M. & Andersen, J. B. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 46  (100479). https:\/\/doi.org\/10.1016\/j.jhepr.2022.100479 (2022).","DOI":"10.1016\/j.jhepr.2022.100479"},{"key":"16379_CR27","doi-asserted-by":"publisher","unstructured":"Uhlen, M. A pathology atlas of the human cancer transcriptome. Science 357 (6352), eaan2507 https:\/\/doi.org\/10.1126\/science.aan2507 (2017).","DOI":"10.1126\/science.aan2507"},{"key":"16379_CR28","unstructured":"Expression of ACLY in liver cancer - The Human Protein Atlas. Zugegriffen: 23  https:\/\/www.proteinatlas.org\/ENSG00000131473-ACLY\/pathology\/liver+cancer (2024)."},{"issue":"22","key":"16379_CR29","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1111\/jcmm.17507","volume":"26","author":"W Bai","year":"2022","unstructured":"Bai, W. et al. Protein succinylation associated with the progress of hepatocellular carcinoma. J. Cell. Mol. Med. 26 (22), 5702\u20135712. https:\/\/doi.org\/10.1111\/jcmm.17507 (2022).","journal-title":"J. Cell. Mol. Med."},{"key":"16379_CR30","doi-asserted-by":"publisher","unstructured":"Chua, H. H. PIM1-Induced cytoplasmic expression of RBMY mediates hepatocellular carcinoma metastasis, cell. Mol. Gastroenterol. Hepatol.  15 (1), 121\u2013152 https:\/\/doi.org\/10.1016\/j.jcmgh.2022.09.014 (2023).","DOI":"10.1016\/j.jcmgh.2022.09.014"},{"issue":"7718","key":"16379_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","volume":"560","author":"U Ben-David","year":"2018","unstructured":"Ben-David, U.,  et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560 (7718), 325\u2013330. https:\/\/doi.org\/10.1038\/s41586-018-0409-3 (2018).","journal-title":"Nature"},{"issue":"52","key":"16379_CR32","doi-asserted-by":"publisher","first-page":"86420","DOI":"10.18632\/oncotarget.13416","volume":"7","author":"W Luo","year":"2016","unstructured":"Luo, W. et al. MYC associated zinc finger protein promotes the invasion and metastasis of hepatocellular carcinoma by inducing epithelial mesenchymal transition. Oncotarget 7 (52), 86420\u201386432. https:\/\/doi.org\/10.18632\/oncotarget.13416 (2016).","journal-title":"Oncotarget"},{"key":"16379_CR33","doi-asserted-by":"publisher","unstructured":"Kahlert, U. D. ZEB1 promotes invasion in human fetal neural stem cells and hypoxic glioma neurospheres, brain pathol. Zurich Switz.  25 (6), 724\u2013732 https:\/\/doi.org\/10.1111\/bpa.12240 (2015).","DOI":"10.1111\/bpa.12240"},{"key":"16379_CR34","doi-asserted-by":"publisher","unstructured":"Zhang, S.  Inhibition of the PINK1-Parkin pathway enhances the lethality of Sorafenib and regorafenib in hepatocellular carcinoma. Front. Pharmacol. 13, 851832 https:\/\/doi.org\/10.3389\/fphar.2022.851832 (2022).","DOI":"10.3389\/fphar.2022.851832"},{"issue":"6","key":"16379_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.14670\/HH-18-443","volume":"37","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Mdivi-1: a promising drug and its underlying mechanisms in the treatment of neurodegenerative diseases. Histol. Histopathol. 37 (6), 505\u2013512. https:\/\/doi.org\/10.14670\/HH-18-443 (2022).","journal-title":"Histol. Histopathol"},{"issue":"3","key":"16379_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3892\/or.2020.7476","volume":"43","author":"M Ma","year":"2020","unstructured":"Ma, M., Lin, X. H., Liu, H. H., Zhang, R. & Chen, R. X. Suppression of DRP1\u2013mediated mitophagy increases the apoptosis of hepatocellular carcinoma cells in the setting of chemotherapy. Oncol. Rep. 43 (3), 1010\u20131018 https:\/\/doi.org\/10.3892\/or.2020.7476 (2020).","journal-title":"Oncol. Rep."},{"issue":"36","key":"16379_CR37","doi-asserted-by":"publisher","first-page":"15105","DOI":"10.1074\/jbc.M117.783175","volume":"292","author":"C Zhang","year":"2017","unstructured":"Zhang, C. Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J. Biol. Chem. 292 (36), 15105\u201315120. https:\/\/doi.org\/10.1074\/jbc.M117.783175 (2017).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"16379_CR38","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3892\/mmr.2019.9866","volume":"19","author":"Y Qin","year":"2019","unstructured":"Qin, Y., Yu, J., Zhang, M., Qin, F. & Lan, X. ZEB1 promotes tumorigenesis and metastasis in hepatocellular carcinoma by regulating the expression of vimentin. Mol. Med. Rep. 19 (3), 2297\u20132306. https:\/\/doi.org\/10.3892\/mmr.2019.9866 (2019).","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"16379_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4103\/ijpm.ijpm_999_21","volume":"65","author":"NS Abouhashem","year":"2022","unstructured":"Abouhashem, N. S., Elwan, A., El, A. S., Hefnawy, H. A. & Atwa.Expression of HnRNP A1, ZEB1, and E-cadherin in hepatocellular carcinoma and their impact on patients\u2019 prognosis and survival. Indian J. Pathol. Microbiol. 65 (3), 589\u2013597. https:\/\/doi.org\/10.4103\/ijpm.ijpm_999_21 (2022).","journal-title":"Indian J. Pathol. Microbiol."},{"key":"16379_CR40","doi-asserted-by":"publisher","unstructured":"Peng, L. Super-Enhancer\u2013Associated long noncoding RNA HCCL5 is activated by ZEB1 and promotes the malignancy of hepatocellular carcinoma. Cancer Res.  79, 3, 572\u2013584 https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0367 (2019).","DOI":"10.1158\/0008-5472.CAN-18-0367"},{"key":"16379_CR41","doi-asserted-by":"publisher","unstructured":"Hashiguchi, M. Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC). BMC Cancer 13 (1),  572  https:\/\/doi.org\/10.1186\/1471-2407-13-572 (2013).","DOI":"10.1186\/1471-2407-13-572"},{"key":"16379_CR42","doi-asserted-by":"publisher","unstructured":"Boulton, D. P. & Caino, M. C. Mitochondrial fission and fusion in tumor progression to metastasis, front. Cell. Dev. Biol. 10 https:\/\/doi.org\/10.3389\/fcell.2022.849962 (2022).","DOI":"10.3389\/fcell.2022.849962"},{"issue":"1","key":"16379_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cac2.12247","volume":"42","author":"D Wu","year":"2022","unstructured":"Wu, D. et al. Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1. Cancer Commun. Lond. Engl. 42 (1), 37\u201355. https:\/\/doi.org\/10.1002\/cac2.12247 (2022).","journal-title":"Cancer Commun. Lond. Engl."},{"key":"16379_CR44","doi-asserted-by":"publisher","unstructured":"Bian, J. Mitochondrial quality control in hepatocellular carcinoma. Front. Oncol.  https:\/\/doi.org\/10.3389\/fonc.2021.713721 (2021).","DOI":"10.3389\/fonc.2021.713721"},{"key":"16379_CR45","doi-asserted-by":"publisher","unstructured":"Zhan, L. Drp1-mediated mitochondrial fission promotes cell proliferation through crosstalk of p53 and NF-\u03baB pathways in hepatocellular carcinoma. Oncotarget 7 (40), 65001\u201365011 https:\/\/doi.org\/10.18632\/oncotarget.11339 (2016).","DOI":"10.18632\/oncotarget.11339"},{"key":"16379_CR46","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1158\/0008-5472.CAN-08-3722","volume":"69","author":"I Samudio","year":"2009","unstructured":"Samudio, I., Fiegl, M. & Andreeff, M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 69, 6, 2163\u20132166. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3722 (2009).","journal-title":"Cancer Res."},{"key":"16379_CR47","doi-asserted-by":"publisher","unstructured":"Marx, N., Ritter, N., Disse, P., Seebohm, G. & Busch, K. B. Detailed analysis of Mdivi-1 effects on complex I and respiratory supercomplex assembly. Sci. Rep. 14 (1), 19673 https:\/\/doi.org\/10.1038\/s41598-024-69748-y (2024).","DOI":"10.1038\/s41598-024-69748-y"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16379-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:16:42Z","timestamp":1755627402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16379-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16379"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16379-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30451"}}